Clinical outcomes of cemented distal femur replacements with all-polyethylene tibial components for oncologic indications

Figure 3 Competing risk analysis for cemented distal femoral replacement with all-polyethylene tibial components for oncologic indications with all-cause revision of the all-polyethylene tibial component (APT) and revision of the APT due to periprosthetic joint infection as the primary endpoints. One- and three-year cumulative incidences were 18.2% (95%CI 2.5%-45.5%) and 47.0% (95%CI 15.1%-74.0%), respectively, with all-cause revision of the APT as the endpoint. One- and three-year cumulative incidences were 10.0% (95%CI 0.5%-37.4%) and 44.0% (95%CI 6.3%-59.3%), respectively, with revision of APT due to periprosthetic joint infection as the endpoint. APT: All-polyethylene tibial; PJI: Periprosthetic joint infection.